Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes

Objective: Biomarkers are needed to characterize heterogeneity within populations at risk for type 1 diabetes. The ratio of proinsulin to C-peptide (PI:C ratio), has been proposed as a biomarker of beta cell dysfunction and is associated with progression to type 1 diabetes. However, relationships be...

Full description

Bibliographic Details
Main Authors: Taylor M. Triolo, Laura Pyle, Sona Seligova, Liping Yu, Kimber Simmons, Peter Gottlieb, Carmella Evans-Molina, Andrea K. Steck
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Journal of Translational Autoimmunity
Online Access:http://www.sciencedirect.com/science/article/pii/S2589909021000095
id doaj-6582df9c9c8745d7a4b1b4ec1ad9e9bf
record_format Article
spelling doaj-6582df9c9c8745d7a4b1b4ec1ad9e9bf2021-03-11T04:25:54ZengElsevierJournal of Translational Autoimmunity2589-90902021-01-014100089Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetesTaylor M. Triolo0Laura Pyle1Sona Seligova2Liping Yu3Kimber Simmons4Peter Gottlieb5Carmella Evans-Molina6Andrea K. Steck7University of Colorado Denver School of Medicine – the Barbara Davis Center for Diabetes, Aurora, CO, USA; Corresponding author.University of Colorado Denver School of Medicine – the Barbara Davis Center for Diabetes, Aurora, CO, USA; University of Colorado Anschutz Medical Campus, Pediatrics, Aurora, CO, USAUniversity of Colorado Denver School of Medicine – the Barbara Davis Center for Diabetes, Aurora, CO, USAUniversity of Colorado Denver School of Medicine – the Barbara Davis Center for Diabetes, Aurora, CO, USAUniversity of Colorado Denver School of Medicine – the Barbara Davis Center for Diabetes, Aurora, CO, USAUniversity of Colorado Denver School of Medicine – the Barbara Davis Center for Diabetes, Aurora, CO, USAIndiana University School of Medicine, Indianapolis, IN, USA; Indiana University Center for Diabetes and Metabolic Diseases. Indianapolis, IN, USAUniversity of Colorado Denver School of Medicine – the Barbara Davis Center for Diabetes, Aurora, CO, USAObjective: Biomarkers are needed to characterize heterogeneity within populations at risk for type 1 diabetes. The ratio of proinsulin to C-peptide (PI:C ratio), has been proposed as a biomarker of beta cell dysfunction and is associated with progression to type 1 diabetes. However, relationships between PI:C ratios and autoantibody type and number have not been examined. We sought to characterize PI:C ratios in multiple islet autoantibody positive, single autoantibody positive and autoantibody negative relatives of individuals with type 1 diabetes. Methods: We measured PI:C ratios and autoantibodies with both electrochemiluminescence (ECL) assays (ECL-IAA, ECL-GADA and ECL-IA2A) and radiobinding (RBA) assays (mIAA, GADA, IA2A and ZnT8A) in 98 relatives of individuals with type 1 diabetes followed in the TrialNet Pathway to Prevention Study at the Barbara Davis Center for a mean of 7.4 ​± ​4.1 years. Of these subjects, eight progressed to T1D, 31 were multiple autoantibody (Ab) positive, 37 were single Ab positive and 22 were Ab negative (by RBA). Results: In cross-sectional analyses, there were no significant differences in PI:C ratios between type 1 diabetes and/or multiple Ab positive subjects (4.16 ​± ​4.06) compared to single Ab positive subjects (4.08 ​± ​4.34) and negative Ab subjects (3.72 ​± ​3.78) (p ​= ​0.92) overall or after adjusting for age, sex and BMI. Higher PI:C ratios were associated with mIAA titers (p ​= ​0.03) and showed an association with ECL-IA2A titers (p ​= ​0.09), but not with ECL-IAA, GADA, ECL-GADA, IA2A nor ZnT8A titers. In mixed-effects longitudinal models, the trajectories of PI:C ratio over time were significantly different between the Ab negative and multiple Ab positive/type 1 diabetes groups, after adjusting for sex, age, and BMI (p ​= ​0.04). Conclusions: PI:C ratio trajectories increase over time in subjects who have multiple Ab or develop type 1 diabetes and may be a helpful biomarker to further characterize and stratify risk of progression to type 1 diabetes over time.http://www.sciencedirect.com/science/article/pii/S2589909021000095
collection DOAJ
language English
format Article
sources DOAJ
author Taylor M. Triolo
Laura Pyle
Sona Seligova
Liping Yu
Kimber Simmons
Peter Gottlieb
Carmella Evans-Molina
Andrea K. Steck
spellingShingle Taylor M. Triolo
Laura Pyle
Sona Seligova
Liping Yu
Kimber Simmons
Peter Gottlieb
Carmella Evans-Molina
Andrea K. Steck
Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes
Journal of Translational Autoimmunity
author_facet Taylor M. Triolo
Laura Pyle
Sona Seligova
Liping Yu
Kimber Simmons
Peter Gottlieb
Carmella Evans-Molina
Andrea K. Steck
author_sort Taylor M. Triolo
title Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes
title_short Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes
title_full Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes
title_fullStr Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes
title_full_unstemmed Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes
title_sort proinsulin:c-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes
publisher Elsevier
series Journal of Translational Autoimmunity
issn 2589-9090
publishDate 2021-01-01
description Objective: Biomarkers are needed to characterize heterogeneity within populations at risk for type 1 diabetes. The ratio of proinsulin to C-peptide (PI:C ratio), has been proposed as a biomarker of beta cell dysfunction and is associated with progression to type 1 diabetes. However, relationships between PI:C ratios and autoantibody type and number have not been examined. We sought to characterize PI:C ratios in multiple islet autoantibody positive, single autoantibody positive and autoantibody negative relatives of individuals with type 1 diabetes. Methods: We measured PI:C ratios and autoantibodies with both electrochemiluminescence (ECL) assays (ECL-IAA, ECL-GADA and ECL-IA2A) and radiobinding (RBA) assays (mIAA, GADA, IA2A and ZnT8A) in 98 relatives of individuals with type 1 diabetes followed in the TrialNet Pathway to Prevention Study at the Barbara Davis Center for a mean of 7.4 ​± ​4.1 years. Of these subjects, eight progressed to T1D, 31 were multiple autoantibody (Ab) positive, 37 were single Ab positive and 22 were Ab negative (by RBA). Results: In cross-sectional analyses, there were no significant differences in PI:C ratios between type 1 diabetes and/or multiple Ab positive subjects (4.16 ​± ​4.06) compared to single Ab positive subjects (4.08 ​± ​4.34) and negative Ab subjects (3.72 ​± ​3.78) (p ​= ​0.92) overall or after adjusting for age, sex and BMI. Higher PI:C ratios were associated with mIAA titers (p ​= ​0.03) and showed an association with ECL-IA2A titers (p ​= ​0.09), but not with ECL-IAA, GADA, ECL-GADA, IA2A nor ZnT8A titers. In mixed-effects longitudinal models, the trajectories of PI:C ratio over time were significantly different between the Ab negative and multiple Ab positive/type 1 diabetes groups, after adjusting for sex, age, and BMI (p ​= ​0.04). Conclusions: PI:C ratio trajectories increase over time in subjects who have multiple Ab or develop type 1 diabetes and may be a helpful biomarker to further characterize and stratify risk of progression to type 1 diabetes over time.
url http://www.sciencedirect.com/science/article/pii/S2589909021000095
work_keys_str_mv AT taylormtriolo proinsulincpeptideratiotrajectoriesovertimeinrelativesatincreasedriskofprogressiontotype1diabetes
AT laurapyle proinsulincpeptideratiotrajectoriesovertimeinrelativesatincreasedriskofprogressiontotype1diabetes
AT sonaseligova proinsulincpeptideratiotrajectoriesovertimeinrelativesatincreasedriskofprogressiontotype1diabetes
AT lipingyu proinsulincpeptideratiotrajectoriesovertimeinrelativesatincreasedriskofprogressiontotype1diabetes
AT kimbersimmons proinsulincpeptideratiotrajectoriesovertimeinrelativesatincreasedriskofprogressiontotype1diabetes
AT petergottlieb proinsulincpeptideratiotrajectoriesovertimeinrelativesatincreasedriskofprogressiontotype1diabetes
AT carmellaevansmolina proinsulincpeptideratiotrajectoriesovertimeinrelativesatincreasedriskofprogressiontotype1diabetes
AT andreaksteck proinsulincpeptideratiotrajectoriesovertimeinrelativesatincreasedriskofprogressiontotype1diabetes
_version_ 1724226019516219392